To date, the administration of recombinant human IL‐15(rhIL‐15) and IL‐15 agonists has been validated by multiple preclinical and clinical trials in various types of cancers [22] but is limited in lung cancer immunotherapy. This evidence concerns the gene IL15 and lung carcinoma.